Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Items 201–300 of 471
Aria, H., Rezaei, M., Nazem, S., Daraei, A., Nikfar, G., Mansoori, B., Bahmanyar, M., Tavassoli, A., Vakil, M. K., & Mansoori, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947885 · Cited by 28
Dietary Manipulation of Amino Acids for Cancer Therapy
Jiménez‐Alonso, J. J., & López‐Lázaro, M. (2023) · Nutrients · doi:10.3390/nu15132879 · Cited by 26
Zhu, W., Cheng, X., Xu, P., Gu, Y., Xu, H., Xu, J., Wang, Y., Zhang, L. W., & Wang, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05650 · Cited by 26
Lin, J., He, X.-L., Zhang, W., & Mo, C. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1584987 · Cited by 28
Metabolic adaptations in cancer progression
Peng‐Winkler, Y., & Fendt, S. (2025) · Physiological Reviews · doi:10.1152/physrev.00037.2024 · Cited by 30
Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors
Xiao, L., Yeung, H., Haber, M., Norris, M. D., & Somers, K. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.05.002 · Cited by 26
Regulation of intrinsic and extrinsic metabolic pathways in tumour‐associated macrophages
Davuluri, G. V. N., & Chan, C. (2022) · FEBS Journal · doi:10.1111/febs.16465 · Cited by 26
The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology
Vanmeerbeek, I., Govaerts, J., Laureano, R. S., Sprooten, J., Naulaerts, S., Borràs, D., Laoui, D., Mazzone, M., Ginderachter, J. A. V., & Garg, A. D. (2022) · Cells · doi:10.3390/cells11233890 · Cited by 26
“Targeting this pathway can shift TAM polarisation towards an M1-like phenotype [81,82].”
BackgroundEmerging frontiers in immuno- and gene therapy for cancer
Gustafson, M. P., Ligon, J. A., Bersenev, A., McCann, C. D., Shah, N. N., & Hanley, P. J. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.002 · Cited by 24
Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer (Review)
Zhou, L., Zhang, Q., Zhu, Q., Zhan, Y., Li, Y., & Huang, X. (2023) · Oncology Letters · doi:10.3892/ol.2023.13745 · Cited by 25
“Glutamine metabo‑ lism not only promotes cell growth, but also creates a TME that benefits from tumor immune escape (64).”
The cross-talk between macrophages and tumor cells as a target for cancer treatment
Aizaz, M., Khan, A. U., Khan, F., Khan, M., Saleh, E. A. M., Nisar, M., & Baran, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1259034 · Cited by 25
Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma
Liu, X., & Yu, Q. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1676338 · Cited by 26
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation
van Geffen, C., Heiss, C., Deißler, A., & Kolahian, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933847 · Cited by 24
Effects of metabolic cancer therapy on tumor microenvironment
Hyroššová, P., Milošević, M., Škoda, J., Vachtenheim, J., Jr., Rohlena, J., & Rohlenová, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046630 · Cited by 25
Yu, T., der Jeught, K. V., Zhu, H., Zhou, Z., Sharma, S., Liu, S., Eyvani, H., So, K. M., Singh, N., Wang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202310308 · Cited by 36
Singh, D., Khan, M. A., & Siddique, H. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114955 · Cited by 23
Zhu, W., Wang, C., Xue, L., Liu, L., Xiao-hong, Y., Liu, Z., Zhang, S., & Luo, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109352 · Cited by 22
Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19
Durante, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087593 · Cited by 23
Glutamine metabolism in tumor metastasis: Genes, mechanisms and the therapeutic targets
Zhong, X., He, Z., Li, Y., Fan, Y., Yu, T., Kang, Y., & Bi, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20656 · Cited by 26
Connections between Metabolism and Epigenetic Modification in MDSCs
Dai, H., Xu, H., Wang, S., & Ma, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197356 · Cited by 23
“Additionally, targeting glutamine metabolism makes it easier for checkpoint blocking drug-resistant tumors to receive immunotherapy [62].”
BackgroundUrea cycle dysregulation: a new frontier in cancer metabolism and immune evasion
Shou, Y., Liu, R., Xiong, H., Xu, K., Chen, X., Huang, L., Zhang, Y., Sheng, H., Zhang, H., & Lü, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02328-3 · Cited by 24
“Concurrently, the carbon skeleton of glutamine is channeled into gluconeogenesis, thereby establishing a biochemical link between the UC and gluconeogenic pathways [64].”
Metabolic manipulation of the tumour immune microenvironment
Wan, M., Ding, Y., Li, Z., Wang, X., & Xu, M. (2021) · Immunology · doi:10.1111/imm.13444 · Cited by 22
“The specific interaction between MDSCs and CD8 antigen can lead to greatly increased levels of inhibitory reactive oxygen species (ROS) in T cells [82].”
BackgroundInfluentialWetzel, T. J., Erfan, S. C., & Ananieva, E. A. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000014 · Cited by 23
“Most recent studies demonstrate that glutamine also plays a role within the TME as it serves as a carbon and nitrogen source for numerous metabolic pathways, including, but not limited to, nucleotide synthesis, amino acid production, extracellular matrix production, and redox balance [78].”
BackgroundMetabolic Barriers to Glioblastoma Immunotherapy
Choudhary, N. R., Osorio, R. C., Oh, J. Y., & Aghi, M. K. (2023) · Cancers · doi:10.3390/cancers15051519 · Cited by 24
“Pro-tumoral immunosuppressive populati ns of Tregs, MDSCs, M2 p larized macrophages, and neutrophils are enriched.”
BackgroundInfluentialIDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy
Park, J., Nah, Y., & Kim, W. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.050 · Cited by 23
Targeting glutamine metabolism crosstalk with tumor immune response
Dong, C., Zhao, Y., Han, Y., Li, M., & Wang, G. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189257 · Cited by 26
Overcoming Cancer Persister Cells by Stabilizing the ATF4 Promoter G‐quadruplex
Xiao, C., Li, Y., Liu, Y., Dong, R., He, X., Lin, Q., Zang, X., Wang, K., Xia, Y., & Kong, L. (2024) · Advanced Science · doi:10.1002/advs.202401748 · Cited by 25
Xu, M., Cui, Y., Wei, S., Cong, X., Chen, Y., Tian, S., Yao, A., Chen, W., & Weng, L. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5337 · Cited by 22
“L‑demethylleucine, to target glutamine metabolism and increase the population of inflam‑ matory TAMs, thereby inhibiting tumor growth (134).”
BackgroundLobel, G. P., Han, N., Arocho, W. A. M., Silber, M., Shoush, J., Noji, M., To, T. K. J., Zhai, L., Lesner, N. P., Simon, M. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412157121 · Cited by 21
Ding, M., Kong, X., Chen, W., Yan, L., Huang, H., Lv, Z., Jiang, P., Mu, A., Huang, C., & Shi, J. (2022) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2022.03.022 · Cited by 19
Glutamine metabolism and radiosensitivity: Beyond the Warburg effect
Alden, R. S., Kamran, M. Z., Bashjawish, B., & Simone, B. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070514 · Cited by 22
Xue, W., Wu, K., Guo, X., Chen, C., Huang, T., Li, L., Liu, B., Chang, H., & Zhao, J. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166982 · Cited by 21
Glutamine deprivation confers immunotherapy resistance by inhibiting IFN-γ signaling in cancer cells
Yuan, Z., Yu, T., Wang, X., Meng, K., Wang, T., Wang, B., Xi, Y., Wang, C., Zeng, C., Hu, S., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107643 · Cited by 21
Liu, Y., Wang, H., Zhao, X., Zhang, J., Zhao, Z., Lian, X., Zhang, J., Kong, F., Hu, T., Wang, T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3115 · Cited by 18
Immunometabolism: a new dimension in immunotherapy resistance
Xiao, C., Xiong, W., Xu, Y., Zou, J. P., Zeng, Y., Liu, J., Peng, Y., Hu, C., & Wu, F. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1012-z · Cited by 20
Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 20
Yang, L., Shao, Y., Zhang, Z., Li, Y., Wang, F., & Yu, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189411 · Cited by 20
Li, W., Chen, J., Li, J., Wang, S., Chen, Z., Zhao, L., Zhao, Y., Gu, L., Liu, J., Zhang, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012321 · Cited by 18
“30 Notably, solute carrier family 38 member 2 (SLC38A2), a high-affinity glutamine transporter upregulated in activated T cells, 31 may serve as a gatekeeper for glutamine-dependent metabolic reprogramming.”
Self-citationLiu, M., Zhang, H., Zhang, L., Liu, X., Zhou, S., Wang, X., Zhong, W., Zhang, J., Wang, B., Zhao, J., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.65402 · Cited by 18
“Recent findings suggest that dampening MDSC suppressor function is an attractive strategy for optimizing cancer immunotherapy and contributing to enhancing the sensitivity of anti-tumor immunotherapy [19, 24, 25].”
BackgroundAkter, Z., Salamat, N., Ali, M. Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072739 · Cited by 18
Ursino, C., Mouric, C., Gros, L., Bonnefoy, N., & Faget, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170321 · Cited by 18
“However in this study total glutamine metabolism was blocked in both cancer and stromal cells, thus it is not possible to descriminate to what extend glutamine uptake and usage specifically by cancer cells might interfere with ICB (89).”
BackgroundMetabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Yang, H., Wu, C.-Y., Powell, J. D., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114030 · Cited by 20
“Likewise, it was found that inhibition of glutamine metabolism employing the DON prodrug JHU-083 can inhibit MDSC generation, inhibit metastasis and promote anti-tumor immunity [232].”
BackgroundSelf-citationMetabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer
Fan, C., Kam, S., & Ramadori, P. (2021) · Cancers · doi:10.3390/cancers13205250 · Cited by 22
“Abolishment of this catabolic process skews macrophage polarization towards the M1 phenotype, and leads to the reduction of myeloid-derived suppressor cells (MDSCs), rendering the tumor more susceptible to immune checkpoint therapy [94,95].”
BackgroundMetabolic control of cancer metastasis: role of amino acids at secondary organ sites
Karno, B. A., Edwards, D. N., & Chen, J. (2023) · Oncogene · doi:10.1038/s41388-023-02868-3 · Cited by 17
“In agreement, several studies have also indicated the importance of GLS and glutamine metabolism, an important producer of α -ketoglutarate, in establishment of lung metastasis in mouse models [52, 71].”
BackgroundMartorana, T. M., Ricciardi, G., Tralongo, P., Fiorentino, V., Pizzimenti, C., Franchina, M., Marino, M. A., Santarpía, M., Tuccari, G., Ieni, A., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156226 · Cited by 16
The Metabolic Control of Myeloid Cells in the Tumor Microenvironment
Ramel, E., Lillo, S., Daher, B., Fioleau, M., Daubon, T., & Saleh, M. (2021) · Cells · doi:10.3390/cells10112960 · Cited by 17
“Surprisingly, the GLS1 inhibition reduced the expression of the Indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the catabolism of tryptophan into the immunosuppressive metabolite L-kynurenine (Kyn) [47] (Figure 2).”
BackgroundMethodFriend and foe: the regulation network of ascites components in ovarian cancer progression
Geng, Z., Pan, X., Xu, J., & Jia, X. (2022) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-022-00698-8 · Cited by 18
Qin, S., Sun, S., Wang, Y., Li, C., Fu, L., Wu, M., Yan, J., Wan, L., Lv, J., & Chen, L. (2024) · Scientific Reports · doi:10.1038/s41598-023-51108-x · Cited by 17
A redox-responsive prodrug for tumor-targeted glutamine restriction
Prange, C. J., Sayed, N. Y. B., Feng, B., Goepfert, C., Ortiz, D., Hu, X., & Tang, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.031 · Cited by 19
Spiga, M., Martini, E., Maffia, M. C., Ciceri, F., Ruggiero, E., Potenza, A., & Bonini, C. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01011-y · Cited by 16
“Inhibition of glutamine metabolism resulted in reduced tumor growth [187] and acted, in turn, on the glycolytic metabolism of tumor cells, favoring oxidative phosphorylation and leading to activation of effector T cells [188].”
Harnessing amino acid pathways to influence myeloid cell function in tumor immunity
Pan, J., Lin, Y., Liu, X., Zhang, X., Liang, T., & Bai, X. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01099-4 · Cited by 18
Claiborne, M. D., & Leone, R. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011191 · Cited by 18
“Further studies suggested an additional mechanism of tumor control arose from alteration in myeloidderived suppressor cell (MDSC) phenotype under glutamine antimetabolite therapy, with these typically pro-tumorigenic cells converting to a more pro-inflammatory phenotype while losing expression of IDO, the enzyme respo…”
BackgroundSelf-citationLi, C., Tao, Y., Chen, Y., Wu, Y., He, Y., Yin, S., Xu, S., & Yu, Y. (2022) · PubMed · Cited by 16
Wang, Y., Zhang, B., Xi, Q., Chen, C., Wang, Z., Li, F., Wang, S., Yang, W., Liang, X., Yu, Z., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102009 · Cited by 15
Zheng, M., Xu, H., Huang, Y., Sun, J., Zhang, H., Lv, Z., Liu, Z., Tang, Z., & Chen, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.054 · Cited by 17
Yu, Z., Huan, X.-Y., Sun, L., Wang, W., Zhou, M.-J., Zhao, M., Chen, P., Yan, H., Pang, P., Shi, X.-Q., et al. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101397 · Cited by 15
Innate myeloid cells in the tumor microenvironment
Duhan, V., & Smyth, M. J. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.01.001 · Cited by 15
Hormone-Glutamine Metabolism: A Critical Regulatory Axis in Endocrine-Related Cancers
Xu, F., Shi, J., Qin, X., Zheng, Z., Chen, M., Lin, Z., Ye, J., & Li, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710086 · Cited by 15
Zhang, X., Halberstam, A. A., Zhu, W., Leitner, B. P., Thakral, D., Bosenberg, M., & Perry, R. J. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00296-7 · Cited by 15
“Supplementing lymphocytes and macrophages with glutamine, for instance, enhances function [19, 20].”
BackgroundFarhangnia, P., & Akbarpour, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00165-8 · Cited by 18
Zhao, Y., Qin, C., Chen, L., Li, Z., Zhao, B., Li, T., Zhang, X., & Wang, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189183 · Cited by 16
Liu, Y., Yang, Y., Yao, R., Hu, Y., Liu, P., Lian, S., Lv, H., Xu, B., & Li, S. (2021) · Archives animal breeding/Archiv für Tierzucht · doi:10.5194/aab-64-231-2021 · Cited by 14
Fu, Z., Du, H., Meng, S., Yao, M., Zhao, P., Li, X., Zheng, X., Zhang, Y., Yang, H., Cai, K., et al. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100449 · Cited by 15
“6-phosphate, and non-essential amino acids) [7,8].”
Lou, Y., Peng, P., Wang, S., Wang, J., Du, P., Zhang, Z., Zheng, J., Liu, P., & Xu, L. X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016776 · Cited by 15
“Targeting glutamine metabolism triggers apoptosis in MDSCs and helps MDSCs differentiate into inflammatory macrophages (21).”
BackgroundMyeloid-derived suppressor cells in head and neck squamous cell carcinoma
He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 15
Chu, X., Ma, J., Li, S., Wang, M., Tian, Y., & Lv, C. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02570-4 · Cited by 15
“More-over, inhibition of tumor glutamine metabolism has been shown to suppress G-CSF production, limit MDSC mobilization, and promote tumor cell apoptosis [265].”
Glutamine binds HSC70 to transduce signals inhibiting IFN-β-mediated immunogenic cell death
Zhang, D., Song, S., Lin, J., Ye, T., Yang, X. M., Jiang, Q., Mi, Y., Zhang, M., Ge, X., Shen, Y., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.02.012 · Cited by 16
Glutamine’s double-edged sword: fueling tumor growth and offering therapeutic hope
Fang, L., Gao, D., Jiang, Z., Li, G., & Li, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578940 · Cited by 15
“This intervention results in a reduced abundance of granulocytic myeloid-derived suppressor cells (G-MDSCs) and M2-like tumor-associated macrophages (TAMs), thereby triggering an anti-tumor response from CD8+ T cells (37).”
InfluentialWang, L., Deng, C., Wu, Z., Zhu, K., & Yang, Z. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04152-2 · Cited by 13
“Notably, Gln utilization differs between M2 and naïve macrophages, influencing their inflammatory phenotypes, where reduced Gln metabolism favors proinflammatory M1 macrophages [11].”
BackgroundNovotná, K., Tenora, L., Prchalová, E., Paule, J., Alt, J., Veeravalli, V., Lam, J., Wu, Y., Šnajdr, I., Gori, S. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01681 · Cited by 13
Self-citationChen, T., Ma, W., Wang, X., Ye, Q., Hou, X., Wang, Y., Jiang, C., Meng, X., Sun, Y., & Cai, J. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.033 · Cited by 13
Metabolic adaptation of myeloid cells in the glioblastoma microenvironment
Essakhi, N., Bertucci, A., Baeza, N., Colin, C., Lavignolle, R., García-González, P. A., Argüello, R. J., Tchoghandjian, A., & Tabouret, É. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431112 · Cited by 14
Liu, Z., Yin, J., Qiu, T., Liu, A., Yu, Y., Yang, S., Liu, Z., & Li, Q. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113832 · Cited by 14
Targeting myeloid cell immunometabolism to improve current non-small cell lung cancer therapies
Runtsch, M. C., Angiari, S., & Kargl, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108893 · Cited by 13
Włodarczyk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157242 · Cited by 14
“Additionally, glutamine affects the differentiation and function of B cells, dendritic cells, and myeloid-derived suppressor cells (MDSCs), highlighting its broad role in immune regulation [59–61].”
Ran, B., Xiao, L., Liu, Y., Zhang, C., Kong, L., Zhang, Y., Gu, X., Jiang, C., & Wu, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.025 · Cited by 16
“In addition, glutamine synthesis is upregulated, and glutamine is secreted into the TME in heterogeneous stromal cell populations, such as cancer-associated fibroblasts, in tumors [182].”
Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion
Zhao, H., Park, J., Wang, Y., Chou, Y.-J., Li, L., Raines, L. N., Hsu, M., Lin, C.-C., Cao, W., Ouyang, Y., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02324-2 · Cited by 13
“These findings hint at a potential therapeutic strategy, specifically targeting glutamine metabolism in myeloid cells to bolster antitumor immunity 54,55 .”
Zhao, J., Dong, Y., Zhang, Y., Wang, J., & Wang, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114585 · Cited by 12
Shettigar, A., Salunke, R., Modi, D. N., & Mukherjee, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110250 · Cited by 12
Myeloid-derived suppressor cells and pulmonary hypertension
Zhang, H., Li, Q., Li, Y., Tang, X., Gu, L., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189195 · Cited by 13
Adamo, A., Frusteri, C., Pilotto, S., Caligola, S., Belluomini, L., Poffe, O., Giacobazzi, L., Dusi, S., Musiu, C., Hu, Y., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2253644 · Cited by 12
“potential therapeutic strategies to limit immunosuppressive myeloid cells are metabolic pathways such as kynurenines derived from the IDO1-associated pathway,(65,66) degradation of arginine, and generation of RNS,(67,68) components of the adenosine pathway,(69) and glutamine metabolism pathway.(70) Interestingly,”
BackgroundCancer Metabolism under Limiting Oxygen Conditions
Kim, L. C., Lesner, N. P., & Simon, M. C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041542 · Cited by 13
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Nangpal, P., Nagpal, N., Angrish, N., & Khare, G. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1572547 · Cited by 12
Hafner, P., Keller, S. J., Chen, X., Alrawashdeh, A. Y., Jumaa, H., Nollmann, F. I., Besson, S., Kemming, J., Gorka, O., Das, T., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02563-7 · Cited by 12
“49 55 Crucially, our data demonstrate a pronounced impact of RAS pathway inhibition on mitochondrial dynamics both in vitro and in vivo, with the effects persisting into therapy-resistant states.”
Wu, Z., Li, N., Gao, Y., Cao, L., Yao, X., & Peng, Q. (2024) · BMC Genomics · doi:10.1186/s12864-023-09946-6 · Cited by 12
“M2 macrophages heavily rely on Gln metabolism, while reduced Gln metabolism can shift macrophages towards the pro-inflammatory M1 phenotype [12].”
BackgroundGlutaminolysis of CD4+ T Cells: A Potential Therapeutic Target in Viral Diseases
Xu, Y., Li, M., Lin, M., Cui, D., & Xie, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s443482 · Cited by 12
Urine Metabolites Enable Fast Detection of COVID-19 Using Mass Spectrometry
Moura, A. V., de Oliveira, D. C., Silva, A., da Rosa, J. R., Garcia, P. H. D., Sanches, P. H. G., Garza, K. Y., Mendes, F. M. M., Lambert, M., Marrero-Gutiérrez, J., et al. (2022) · Metabolites · doi:10.3390/metabo12111056 · Cited by 11
“Glutamine (Gln) Aminoacyl-tRNA biosynthesis D-Glutamine and D-glutamate metabolism Nitrogen metabolism Glyoxylate and dicarboxylate metabolism Arginine biosynthesis Immune regulation [74,91,92]; Metabolic changes [46,93]; Oxidative stress [94,95] [70–78]”
BackgroundPlasticity of myeloid-derived suppressor cells in cancer and cancer therapy
LV, J., Zhong, X., Wang, L., & Fan, W. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.060063 · Cited by 15
“Besides IDO inhibition, targeting glutamine metabolism promotes the differentiation of MDSCs into pro-in fl ammatory TAMs [55].”
Targeting Metabolic Reprogramming in Tumor: From Mechanisms to Precision Immunotherapies
Zhang, T., Gao, P., & Sun, L. (2025) · MedComm – Oncology · doi:10.1002/mog2.70045 · Cited by 12
Enzymatic depletion of circulating glutamine is immunosuppressive in cancers
Kumar, M., Leekha, A., Nandy, S., Kulkarni, R. S., Martinez-Paniagua, M. A., Sefat, K. M. S. R., Willson, R. C., & Varadarajan, N. (2024) · iScience · doi:10.1016/j.isci.2024.109817 · Cited by 10
“16,17 An improved understanding of the role of the immune system and the remarkable success of immunother-apies 18,19 has renewed focus on the role of extracellular glutamine within the tumor microenvironment (TME).”
BackgroundInfluentialFeng, S., Wang, D., Jin, Y., Huang, S., Liang, T., Sun, W., Du, X., Zhuo, L., Shan, C., Zhang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114300 · Cited by 12
The Role and Treatment Strategies of Ammonia-Related Metabolism in Tumor Microenvironment
Ye, Q., Li, D., Zou, Y., & Yuan, Y. (2024) · Current Gene Therapy · doi:10.2174/0115665232301222240603100840 · Cited by 11
Zhao, Z., Jia, H., Sun, Z., Li, Y., & Liu, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485109 · Cited by 11
Natural products targeting the metabolism of amino acids: from discovery to synthetic development
Kim, H. S., Hassan, A. H. E., Moon, K., & Sim, J. (2025) · Natural Product Reports · doi:10.1039/d5np00039d · Cited by 10
The metabolic regulation of tumor-associated macrophage reprogramming
Fan, H., Lu, D., Yin, X., Sun, H., Wang, Z., Sun, H., Li, Y., Li, Y., Zhou, Z., Chen, L., et al. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.10.006 · Cited by 10
Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights
Wang, Y., Huang, D., Wang, R., Yin, J.-J., Pei, J., & Zhang, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1706040 · Cited by 10
The metabolic basis of regulated cell death
Liu, J., Wang, J., Kang, R., Kroemer, G., & Tang, D. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.001 · Cited by 9
Tumor Microenvironment: Obstacles and Opportunities for T Cell–Based Tumor Immunotherapies
Hu, M., Zhao, Y., Zhang, N., Gong, F., Zhang, W., Dong, C., Dai, J., & Wang, J. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0747 · Cited by 11
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.